Regeneron Pharmaceuticals (REGN) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

• 11/20/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $615.00 to $700.00. They now have an “equal weight” rating on the stock.
• 11/18/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Regeneron Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/13/2025 – Regeneron Pharmaceuticals is now covered by analysts at Scotiabank. They set a “sector perform” rating and a $650.00 price target on the stock.
• 11/12/2025 – Regeneron Pharmaceuticals was upgraded by analysts at Scotiabank to a “hold” rating.
• 11/9/2025 – Regeneron Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/7/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at UBS Group AG from $595.00 to $660.00. They now have a “neutral” rating on the stock.
• 11/1/2025 – Regeneron Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $660.00 to $700.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $704.00 to $708.00. They now have a “sector perform” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $580.00 to $615.00. They now have an “equal weight” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $678.00 to $740.00. They now have an “overweight” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Guggenheim from $815.00 to $865.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $543.00 to $627.00. They now have an “underperform” rating on the stock.
• 10/23/2025 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $850.00 price target on the stock.
• 10/14/2025 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $850.00 price target on the stock.
• 10/13/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $650.00 to $660.00. They now have a “buy” rating on the stock.
• 10/10/2025 – Regeneron Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $761.00 to $756.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – Regeneron Pharmaceuticals had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Regeneron Pharmaceuticals had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.